Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A Podcast
{{output}}
In the EV-302/KEYNOTE-A39 trial (NCT04223856), enfortumab vedotin + pembrolizumab (EV + P) became the first treatment in decades to demonstrate significant survival benefit compared with platinum-based chemotherapy in the first-line setting for patients with l... ...
